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Summary.-The effector arm of antibody-dependent cellular cytotoxicity (ADCC)
was evaluated using 5lCr-labelled chicken erythrocytes as targets in BALB/c mice
transplanted with the Moloney sarcoma virus-induced tumours T-MSV and MS2,
and in C57BL/6 mice transplanted with the chemically induced FS6 sarcoma, Lewis
lung carcinoma and B16 melanoma. Tumour-bearing animals showed higher levels
of ADCC than normal mice, a stimulation confirmed in MS2-bearing mice, using
SL2 lymphoma cells as targets in a cytostasis assay.
ADCC effector-cell capacity was higher in animals transplanted with the immuno-
genic, spontaneously regressing T-MSV than in mice bearing the poorly immuno-
genic metastasizing MS2 sarcoma. The increased ADCC activity detectable in the
spleen oftumour-bearing hosts was not abolished by removal ofphagocytic-adherent
cells.
IT is now well established that lymphoid
cells can express cytotoxic activity for
target cells in vitro in the presence of
specific antibody (MacLennan, 1972; Perl-
mann, Perlmann and AWigzell, 1972).
Effector cells involved in antibody-de-
pendent cellular cytotoxicity (ADCC),
hereafter referred to as K cells, appear
to be heterogenous, both macrophages
andc nonphagocytic cells having been
reported to express cytotoxicity for anti-
body-coated target cells (Greenberg et
al., 1975b; Zighelboim, Bonavida and
Fahey, 1973; Sanderson and Taylor,
1976; Evans and Alexander, 1 976; Jolley,
Boyle and Ormerod, 1976).
The role played by ADCC in tumour-
bearing animals is still not entirely clear.
Serum collected from rodents with chemi-
cal or virus-induced tumours can render
normal. lymphoid cells cytotoxic for tu-
mour target cells or increase the cytotoxi-
city of immune lymphocytes (Pollack,
1973; Ortiz de Landazuri, Kedar and
Fahey, 1974; Basham and Currie, 1974).
Moreover, passive transfer of cell-depen-
dent antibodies results in significant
antitumoral effects in vivo, thus suggesting
that ADCC could represent an important
antitumoral effector mechanism (Hersey,
1973; Zighelboim, Bonavida and Fahey,
1974).
Little effort has been made to analyse
possible modifications of K-cell activity
in tumour-bearing animals. In a recent
report, mice bearing an immunogenic
chemically induced sarcoma were found
to have increased ADCC effector capacity
(Ghaffar, Calder and Irvine, 1976). The
present investigation was designed to
analyse K-cell activity in mice transplant-
ed with Moloney sarcoma virus (MSV)-
induced tumours differing in immuno-
genicity and metastasizing capacity. Tu-
mour-bearing animals showed increased
ADCC effector capacity not attributable
to phagocytic-adherent cells. Activation
of the cellular arm of ADCC reachedA. MANTOVANI ET AL.
higher levels in mice bearing immunogenic
tumours than in animals transplanted
with poorly immunogenic metastasizing
neoplasms.
MATERIALS AND METHODS
Animals.-Male C57BL/6 and BALB/c
mice (6-8 weeks old) were obtained from
Charles River, Calco, Italy.
Tumours.-MSV-induced sarcomas T-MSV
and MS2 have previously been described
in detail (Giuliani, Casazza and Di Marco,
1974; Di Marco et al., 1976; Giuliani et al.,
1977). Briefly, the T-MSV sarcoma was
originally induced in BALB/c mice by
infection with MSV, and maintained in
syngeneic hosts by i.m. injection of 106
tumour cells. The tumour, which was em-
ployed between the 37th and the 40th
passage, is strongly immunogenic and re-
gresses spontaneously by Day 20 under
these experimental conditions.
The MS2 sarcoma was obtained by i.m.
injection in BALB/c mice of an in vitro cell
line established by serial culture of a primary
MSV-induced sarcoma. This tumour is not
immunogenic, as assessed by concomitant
immunity experiments; it grows progressively
and metastasizes to the lung.
The MS2 sarcoma was maintained in
syngeneic BALB/c mice by i.m. inoculation
of 106 tumour cells. The macrophage contents
of the T-MSV and MS2 sarcomas, assessed
as described by Evans (1972), are 430o and
3-70o respectively. Chemically induced FS6
fibrosarcoma was obtained through the
courtesy of Dr R. Evans, Chester Beatty
Research Institute, Sutton, Surrey, and
maintained by i.m. injections of 106 cells
in syngeneic C57BL/6 hosts. The tumour
is immunogenic, does not metastasize (Manto-
vani, Evans and Alexander, 1977) and has a
macrophage content of 3900.
Lewis lung carcinoma (3LL) and B16
melanoma, both ofspontaneous origin (Geran
et al., 1972), were maintained in syngeneic
C57BL/6 mice by i.m. transfer of 2 x 105
tumour cells. Both tumours spontaneously
metastasize to the lung and are poorly
immunogenic, as assessed by concomitant
immunity experiments performed as pre-
viously described (Giuliani et al., 1974). The
two tumours have a macrophage content
of ~2%
Spleen cells.-Spleens were minced with
scissors in minimal essential medium (MEM),
and resuspended with a Pasteur pipette.
After washing twice with MEM, the cells
w-ere resuspended in RPMI 1640 medium
(Gibco Biocult, Glasgow, Scotland) supple-
mented with 10% foetal bovine serum
(growth medium). To remove phagocytic-
adherent cells, splenocyte preparations were
exposed to carbonyl iron (10 mg/107 cells/ml)
as described by Lundgren, Zukoski and
Moller (1968).
After this procedure, the number of
phagocytic cells was below 10%, as asse,sed
by Neutral Red uptake. The effectiveness
of phagocyte removal was additionally
checked as described by Bennett (1966)
and, after 5 days of culturing 2-5 x 106
spleen cells in plastic Petri dishes (Cat. No.
25000, Corning, USA), no mature macro-
phages could be detected morphologically
in Giemsa-stained preparations. Finally, in
agreement with previous data (Kirchner,
Holden and Herberman, 1975), phagocyte
removal by this method also resulted in
the disappearance of Corynebacterium par-
vum-induced spleen macrophage cytotoxicity
against lymphoma cells, thus providing a
functional demonstration of phagocyte re-
moval.
ADCC assay.-ADCC effector cell activity
was measured using chicken erythrocytes
(CRBC) as targets, as recently described in
detail (Tagliabue et al., 1977). Briefly,
5 x 104 51Cr-labelled CRBC were mixed in
plastic tubes wvith splenocytes employing
a range (from 5: 1 to 90: 1) of attacker:
target-cell (A: T) ratios and with an optimal
dilution of mouse anti-CRBC serum. Tubes
were incubated for 270 min at 37°C in
humidified air with 5Qo CO2 and the per-
centage ofspecific cytotoxicity was calculated
according to the formula:
00 51Cr release with antibody and spleen cells
0/51 Cr release with spleen cells alone
0°, maximum 51Cr release
- 00 51Cr release with spleen cells alone
Isotope release in the absence of anti-CRBC
antibody never exceeded 500, and was
similar in all experimental groups. Maximal
isotope release, obtained by osmotic lysis
of CRBC, averaged 700g. A semilog plot
of the specific cytotoxicity values versus
the number of effector cells per sample was
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obtained, and the number of cells giving
500o specific cytotoxicity was arbitrarily
defined as one lytic unit (LU50). This ap-
proach permitted quantitative estimation of
the total cytotoxicity of the organ (Tag-
liabue et al., 1977).
When SL2 lymphoma cells of DBA/2
origin were used as targets, a DNA-synthesis
assay was used. The test was performed as
previously described, except for the use of
tritiated thymidine ([3H]-TdR) instead of
125IUdR (Mantovani, 1977). Briefly, 5 x 104
SL2 lymphoma cells in 1 ml growth medium,
sensitized with 04 ml of a 1: 200 diluted
anti-SL2 alloantiserum raised in C3H mice,
were cultivated in the wells of Costar trays
(Cat. No. 3524, Costar, Cambridge, Mass.,
U.S.A.) with different numbers ofsplenocytes
in a final volume of 1-2 ml growth medium.
After 48 h at 37°C the cells were transferred
to plastic tubes, washed twice with MEM
and incubated for 3 h with 1 ,tCi [3H]-TdR
(sp. act. 5 Ci/mmol, Amersham, England)
in 1 ml growth medium. Acid-precipitable
radioactivity was then determined as pre-
viously described (Vecchi et al., 1976).
Statistical analysis. At least 5 mice per
experimental group were employed through-
out and results obtained with triplicate
tubes per A : T were analysed by Dunnet's
test.
RESULTS
Fig. 1 shows a typical experiment
in which K-cell activity was evaluated
in BALB/c mice 2 weeks after implanta-
tion of 106 cells of the T-MSV and MS2
sarcomas. Splenocytes obtained from tu-
mour-bearing mice were significantly
(P < 0-01) more effective in lysing anti-
body-coated CRBC than normal spleen
cells, the number of lymphoid cells re-
quired to obtain 5000 lysis being 35,
12 and 7 x 105 for normal, MS2 and
T-MSV-transplanted animals respectively.
The kinetics of K-cell activation in
these tumour systems is presented in
Fig. 2(a); a significant (P < 0.01) increase
in splenocyte cytotoxicity was detected
on Day 7 and reached its peak on Day 14
in both systems, remaining thereafter
above control values until Day 28, when
observation was discontinued. Spleen cells
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FIG. 1. K-cell activity in mice transplanted
with the T-MSV and MS2 sarcomas. The
activity was assayed 2 weeks after tumour
implantation, using CRBC as targets.
from T-MSV-inoculated animals appeared
somewhat more effective than splenocytes
from MS2-bearing mice, except on Day
28. when cytotoxicity was similar in
animals from both groups.
Results presented in Fig. 1 and 2(a)
were obtained using a 4-h 5lCr-release
assay, but similar stimulation of ADCC
was detectable in tumour-bearing animals
using a 24-h incubation.
In order to obtain a measure of total
spleen ADCC-effector capacity, the LU50
values were related to spleen cell counts,
which were markedly increased in tumour-
bearing mice (Fig. 2(b) and (c)). Under
these conditions, stimulation of ADCC,
expressed as total LU50 values per spleen,
in tumour-bearing hosts was even clearer
than from the cytotoxicity data. More-
over the difference between the T-MSV
and MS2 sarcomas was amplified as
a consequence of the higher degree of
splenomegaly in mice transplanted with
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the former; mice bearing the immuno-
genic T-MSV sarcoma showed at least
twice as many LU50 per spleen as animals
injected with the poorly immunogenic
MS2 tumour, except on Day 28 when
ADCC activity in the T-MSV group was
only 35% higher than in mice trans-
planted with the MS2 sarcoma. Mean
survival time of MS2-bearing animals
was 43 days (range 29-51). K-cell activity
was then evaluated employing SL2 tu-
mour cells as targets. We could not
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FIG. 2.-Time-course of ADCC activity in
mice transplanted with T-MSV and MS2
sarcomas. CRBC were used as targets.
(a) Number of spleen cells necessary to
give 50% specific cytotoxicity (LU5o);
(b) number of spleen cells; (c) ADCC
activity expressed as LU50 per spleen.
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FIG. 3.-ADCC-effector-cell activity in mice
transplanted with MS2 sarcoma. ADCC
was evaluated 3 weeks after tumour
implantation, using SL2 lymphoma cells
as targets in an [3H]TdR-uptake assay.
Continuous anddottedlinesrefer to samples
without and with antibody respectively.
I i 1'4 21
Day after tumour implantation
Fig. (2b)
obtain significant levels of lysis of tumour
target cells in the presence of xenogeneic
or allogeneic antibody using murine
splenocytes as effectors. However, under
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FIG. 4.-ADCC-effector-cell activity in mice
transplanted with the FS6 sarcoma, the
3LL carcinoma or the B16 melanoma. Acti-
vity was assayed 2 weeks after tumour
implantation, using CRBC as targets.
these conditions, antibody-induced cell-
mediated tumour-cell cytostasis was read-
ily observable, thus confirming thatinhibi-
tion of tumour-cell DNA synthesis can
represent a more sensitive indicator of
ADCC than lysis of tumour target cells
(Greenberg, Shen and Medley, 1975a;
Evans and Alexander, 1976). Spleen cells
from MS2-transplanted mice were em-
ployed as attacker cells in these experi-
ments, because they did not nonspecific-
ally inhibit growth and DNA synthesis
of tumour cells, as opposed to lymphoid
cells from T-MSV sarcoma-bearing mice
(unpublished observations). As shown in
Fig. 3, splenocytes collected from MS2
transplanted mice were significantly more
inhibitory than normal BALB/c spleen
cells of SL2 lymphoma DNA synthesis in
the presence of specific alloantibody.
Stimulation of ADCC in cancer-bearing
hosts was confirmed in C57BL/6 mice
transplanted with FS6, 3LL and B16
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FIG. 5.- Effect of carbonyl iron on the
stimulation of ADCC-effector-cell activity detectable in tumour-bearing animals.
Tests were made 2 weeks after tumour
implantation, using CRBC as targets.
Dotted lines refer to carbonyl-iron-treated
splenocytes.
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tumours employing CRBC as targets.
As illustrated by the representative ex-
periment in Fig. 4, spleen cells obtained
two weeks after tumour implantation
lysed antibody-coated CRBC more effi-
ciently than controls, splenocytes from
FS6-transplanted mice being significantly
more active than lymphoid cells from
animals inoculated with the poorly im-
munogenic B16 and 3LL tumours.
In a series of experiments, the nature
of effector cells responsible for stimulation
of ADCC in tumour-bearing mice was
investigated. In these tests, ADCC was
evaluated using CRBC as targets, and
splenocytes obtained 2 weeks after im-
plantation of the T-MSV and FS6 sar-
comas as effectors. Removal ofphagocytic-
adherent cells by carbonyl iron signifi-
cantly reduced K-cell activity of both
normal and tumorous splenocytes. How-
ever, phagocyte-deprived spleen cells from
tumour-bearing mice still showed higher
levels of ADCC-effector capacity than
similarly treated normal lymphoid cells.
DISCUSSION
The results presented here show that
mice transplanted with experimental tu-
mours of viral, chemical or spontaneous
origin display increased K-cell effector
capacity against CRBC and tumour cells.
These findings confirm and extend a
previous observation reported by G(haffar
and co-workers, using a murine chemically
induced sarcoma and CRBC as targets
(Ghaffar et al., 1976) In their study,
stimulation of K-cell activity increased
with time after tumour implantation and
was directly correlated with tumour size.
Moreover, the presence of an actively
growing neoplasm was a prerequisite for
increased ADCC activity. A similar in-
crease of ADCC-effector capacity with
time was observed here in mice inoculated
with the progressively growing M82 sar-
coma. On the other hand, elevated K-cell
activity was still detectable 21 and 28
days after T-MSV tumour implantation
(i.e. in tumour-free animals, spontaneous
regression of this sarcoma being complete
by Day 20). The persistence of elevated
ADCC levels after complete rejection of
the T-MSV sarcoma might be due to
the presence of an MSV-related virus
in the lymphoid organs of regressor mice
(Giuliani et al., 1973). Effector cells
responsible for simulation of ADCC in
tumour-bearing mice were not positively
identified in this study. Both macrophages
and non-adherent non-phagocytic cells
can show ADCC against tumour cells
and CRBC (Zighelboim et al., 1973;
Greenberg et al., 1.975b; Jolley et al., 1976;
Sanderson and Taylor, 1976; Evans and
Alexander, 1]976). Since, after removal
of phagocytic-adherent cells by carbonyl
iron, spleen cells from tuLmour-bearing
mice were still more cytotoxic than
phagocyte-deprived normal splenocytes
for antibody-coated CRBC, it is suggested
that mature phagocytes do not account
for the increased K-cell activity detected
in tumour bearers.
The biological mechanisms responsible
for activation of the cellular arm of
ADCC in tumour-bearing animals are
still unclear. K-cell stimulation was de-
tectable in both immunogenic and poorly
immunogenic tumours, although signifi-
cantly higher levels of ADCC-effector
function were observed in mice bearing
immunogenic nonmetastasizing neoplasms.
Thus tumour immunogenicity could repre-
sent an imporant determinant of the
degree of K-cell activation in tumour-
bearing mice. In view of the available
evidence that ADCC may be one mech-
anism in the control of tumour growth
(Pollack, 1973; Ortiz de Landazuri et
al., 1974; Basham and Currie, 1974;
Hersey, 1937; Zighelboim et al., 1974)
and of the finding reported here, that
mice bearing an immunogenic nonmeta-
stasizing MSV-induced sarcoma show
higher levels of K-cell activity than
animals inoculated with metastasizing
MSV-induced neoplasms, it is tempting
to speculate that the degree of K-cell
activation may play a role in determining
the biological behaviour of experimental
tumours.
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The observation that tumour-bearing
animals show increased K-cell effector
capacity apparently contrasts with the
depression of ADCC previously reported
in cancer patients (Ting and Terasaki,
1974). However, the significance of this
discrepancy appears doubtful, since little
information was given in the clinical
study concerning the therapeutic proto-
cols employed, and it is known that
surgery, chemotherapy and radiotherapy
can inhibit K-cell activity (Campbell et
al., 1976; Vose and Moudgil, 1976;
Purves and Berenbaum, 1975). ADCC-
effector function in cancer patients is
currently being re-evaluated inthis labora-
tory.
This work was supported by NIH
Grant No. 5 ROI-CA-12764.
A.M. is the recipient of a fellowship
from the Anna Villa Rusconi Foundation.
We thank Miss P. Savi and Mr A.
Ubaldi for valuable technical assistance.
REFERENCES
BASHAM, C. & CURRIE, G. A. (1974) Development
of Specific Cell-dependent Antibody during
Growth of a Syngeneic Rat Sarcoma. Br. J.
Cancer, 29, 189.
BE;NNETT, B. (1966) Isolation and Cultivation in
vitro of Macrophages from Various Sources in
the Mouse. Am. J. Pathot., 48, 165.
CAMPBELL, A. C., WIERNIK, G., WOOD, J., HERSEY,
P., WALLER, C. A. & MACLENNAN, J. C. M.
(1976) Characteristics of the Lymphopenia
Induced by Radiotherapy. Clin. Exp. Immunol.,
23, 200.
Di MARCO, A., DASDIA, T., GIULIANI, F., NECCO,
A., CASAZZA, A. M., MORA, P. T., LUBORSKY,
S. W. & WATERS, L. (1976) Biological Properties
of Cell Lines Derived from Moloney Virus-
induced Sarcoma. Tumori, 62, 415.
EVANS, R. (1972) Macrophages in Syngeneic Animal
Tumours. Tran8plantation, 14, 468.
EVANS, R. & ALEXANDER, P. (1976) Mechanisms
of Extracellular Killing of Nucleated Mammalian
Cells by Macrophages. In Immunobiology of the
Macrophage8. Ed. D. S. Nelson. New York:
Academic Press, p. 535.
GERAN, R. I., GREENBERG, N. H., MACDONALD,
M. M., SCHUMACHER, A. M. & ABBOTT, B. J.
(1972) Protocols for Screening Chemical Agents
and Natural Products against Animal Tumors
and Other Biological Systems. Cancer Chemother.
Rep., 3, 1.
GHAFFAR, A., CALDER, E. A. & IRVINE, W. J. (1976)
K Cell Cytotoxicity against Antibody-coated
Chicken Erythrocytes in Tumor-bearing Mice:
Its Development with Progressively Growing
Tumor and the Effect of Immunization against
the Tumor. J. Immunol., 116, 315.
GIULIANI, F., CASAZZA, A. M. & Di MARCO, A.
(1974) Virologic and Immunologic Properties
and Response to Daunomycin and Adriamycin
of a Non-regressing Mouse Tumor Derived from
MSV-induced Sarcoma. Biomed. Express, 21,
435.
GIULIANI, F., CASAZZA, A. M., SORANZO, C. &
Di MARCO, A. (1977) Effect of Pretreatment with
Immune Serum on Murine Sarcoma Virus
(Moloney) Tumour Induction and Growth. Br. J.
Cancer, 35, 190.
GIULIANI, F., SORANZO, C., CASAZZA, A. M. &
Di MARco, A. (1973) Omogenicita di Cellule
Linfoidi Immuni verso il Sarcoma Murino di
Moloney. Tumori, 59, 269.
GREENBERG, A. H., SHEN, L. & MEDLEY, G. (1975a)
Characteristics of the Effector Cells Mediating
Cytotoxicity against Antibody-coated Target
Cells. I. Phagocytic and Non-phagocytic Effector
Cell Activity against Erythrocyte and Tumour
Target Cells in a 51Cr Release Cytotoxicity
Assay and [1251] IUdR Growth Inhibition Assay.
Immunology, 29, 719.
GREENBERG, A. H., SHEN, L., WALKER, L., ARNAIZ-
VILLENA, A. & ROITT, I. M. (1975b) Characteristics
of the Effector Cells Mediating Cytotoxicity
against Antibody-coated Target Cells. II. The
Mouse Nonadherent K Cell. Eur. J. Immunol.,
5, 474.
HERSEY, P. (1973) New Look at Antiserum Therapy
of Leukaemia. Nature, (New Biol.), 244, 22.
JOLLEY, G. M., BOYLE, M. D. P. & ORMEROD, M. G.
(1976) The Destruction of Allogeneic Tumor
Cells by Antibody and Adherent Cells from
Peritoneal Cavities of Mice. Cell. Immunol., 22,
262.
KIRCHNER, H., HOLDEN, H. T. & HERBERMAN,
R. B. (1975) Splenic Suppressor Macrophages
Induced in Mice by Injection of Corynebacterium
parvum. J. Immunol., 115, 1212.
LUNDGREN, G., ZUKOSKI, C. F. & MOLLER, G.
(1968) Differential Effects of Human Granulo-
cytes and Lymphocytes on Human Fibroblasts
in vitro. Clin. Exp. Immunol., 3, 817.
MAcLENNAN, I. C. (1972) Antibody in the Induction
and Inhibition of Lymphocyte Cytotoxicity.
Transplant Rev., 13, 67.
MANTOVANI, A. (1977) In vitro and in vivo Cyto-
toxicity of Adriamycin and Daunomycin for
Murine Macrophages. Cancer Res., 37, 815.
MANTOVANI, A., EVANS, R. & ALEXANDER, P.
(1977) Non-specific Cytotoxicity of Spleen Cells
in Mice Bearing Transplanted Chemically-induced
Fibrosarcomas. Br. J. Cancer, 36, 35.
ORTIZ DE LANDAZURI, M., KEDAR, E. & FAHEY,
J. L. (1974) Antibody-dependent Cellular Cyto-
toxicity to a Syngeneic Gross Virus-induced
Lymphoma. J. natn. Cancer Inst., 52, 147.
PERLMANN, P., PERLMANN, H. & WIGZELL, H.
(1972) Lymphocyte Mediated Cytotoxicity in
vitro. Induction and Inhibition by Humoral
Antibody and Nature ofEffector Cells. Transplant.
Rev., 13, 91.
POLLACK, S. (1973) Specific "Arming" of Normal
Lymph-node Cells by Sera from Tumor-bearing
Mice. Int. J. Cancer, 11, 138.460 A. MANTOVANI ET AL.
PURVES, E. C. & BERENBAUM, M. C. (1975) Selective
Suppression of Murine Antibody-dependent Cell-
mediated Cytotoxicity by Azathioprine. Trans-
plantation, 19, 274.
SANDERSON, C. J. & TAYLOR, G. A. (1976) Antibody-
dependent Cell-mediated Cytotoxicity in the
Rat. The Role of Macrophages. Immunology,
30, 117.
TAGLIABUE, A., MANTOVANI, A., POLENTARUTTI,
N., VECCHI, A. & SPREAFICO, F. (1977) Effect of
Immunomodulators or Effector Cells Involved
in Antibody-dependent Cellular Cytotoxicity.
J. natn. Cancer Inst. (in press).
TING, A. & TERASAKI, P. I. (1974) Depressed
Lymphocyte-mediated Killing of Sensitized Tar-
gets in Cancer Patients. Cancer Res., 34, 2694.
VEOcHI, A., MANTOVANI, A., TAGLIABUE, A. &
SPREAFICO, F. (1976) A Characterization of the
Immunosuppressive Activity of Adriamycin and
Daunomycin on Humoral Antibody Production
and Tumor Allograft Rejection. Cancer Res.,
36, 1222.
VOSE, B. M. & MOUDGIL, G. C. (1976) Post-operative
Depression of Antibody-dependent Lymphocyte
Cytotoxicity following Minor Surgery and Anaes-
thesia. Immunology, 30, 123.
ZIGHELBOIM, J., BONAVIDA, B. & FAHEY, J. L.
(1973) Evidence for Several Cell Populations
Active in Antibody Dependent Cellular Cyto-
toxicity. J. Immunol., 111, 1737.
ZIGHELBOIM, J., BONAVIDA, B. & FAHEY, J. L.
(1974) Antibody-mediated in vivo Suppression
of EL4 Leukemia in a Syngeneic Host. J. natn.
Cancer Inst., 52, 879.